The FDA has issued a tentative approval for Lantheus’ PNT2003, a generic version of Novartis’ radioligand therapy Lutathera (lutetium Lu 177 dotatate), even as Novartis pursues multi‑patent litigation against Lantheus and other challengers. The decision clears a regulatory step but leaves commercial launch contingent on the outcome of ongoing Hatch‑Waxman disputes and remaining patent injunctions. Novartis sued Lantheus in 2024 alleging infringement across multiple formulation and process patents covering Lutathera; the litigation has already drawn unusual scrutiny from the Delaware court. Legal experts warn that radiopharmaceuticals often hinge on manufacturing and formulation patents rather than core molecule claims, complicating the typical ANDA pathway. What happened: Lantheus secured tentative approval from the FDA for PNT2003, which treats somatostatin receptor‑positive gastroenteropancreatic neuroendocrine tumors. Why it matters: a full approval could create a price and supply challenge for Novartis’ franchise, but commercial entry remains blocked by active patent litigation and potential stays under the Hatch‑Waxman framework.